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Abstract
Background: UK National Dementia Strategies prioritise fair access to dementia treatments for the whole population. We
investigated for the ﬁrst time inequalities in NHS national dementia prescribing and how they have varied between UK coun-
tries and over time.
Method: we investigated the association between Townsend deprivation score and anti-dementia drug prescribing in 77,045
dementia patients from UK primary care records from 2002 to 2013.
Results: we included 77,045 patients with recorded dementia diagnosis or anti-dementia drug prescription. Least deprived
patients were 25% more likely to be initiated on anti-dementia drugs than the most deprived (adjusted incidence rate ratio 1.25,
95% conﬁdence interval 1.19–1.31). This was driven by data from English practices where prescribing rates were consistently
lower in more deprived patients compared with Scotland, Northern Ireland and Wales, where prescribing was not related to de-
privation quintile. Compared with English practices, anti-dementia medication was prescribed more often in Northern Irish
(1.81, 1.41–2.34) and less in Welsh practices (0.68, 0.55–0.82), with a trend towards more prescribing in Scottish practices
(1.14, 0.98–1.32). Drug initiation rates were also higher in younger people and men.
Conclusion: four years after the English National Dementia Strategy, there is no evidence that the Strategy’s key objective of
reducing treatment inequalities is being achieved. Higher overall anti-dementia drug prescribing in Scottish and Northern Irish
practices, and differing clinical guidelines in Scotland from other UK countries might explain greater equality in prescribing in
these countries. Strategies to offer treatment to more deprived people with dementia in England are needed.
Keywords: dementia, healthcare disparities, cholinesterase inhibitor, older people
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Introduction
Around 6.5% of the UK population aged 65 and over have
dementia [1, 2]. Cholinesterase inhibitors and memantine
beneﬁcially affect cognitive, functional and global outcomes
in Alzheimer’s disease and are the only drugs NICE
(National Institute for Health and Clinical Excellence) rec-
ommend for dementia.
NICE recommended cholinesterase inhibitors for mild
and moderate Alzheimer’s disease in 2001; restricted this to
moderate dementia in 2006 on cost beneﬁt grounds, then
reversed these restrictions in 2009; since 2011, they have also
recommended memantine. NICE technology appraisals
apply in England, Wales and Northern Ireland. NHS
Scotland [3] allows Scottish clinicians to follow NICE or
Scottish Intercollegiate Guidelines Network (SIGN) guide-
lines; the less restrictive SIGN guidelines, recommending
cholinesterase inhibitors for any severity dementia since 2006
are probably more inﬂuential [4]. National Dementia
Strategies for England (2009), Scotland (2010) and Wales
(2009) promote fair access to treatment. UK anti-dementia
drug prescriptions [5] and specialist referrals for dementia
have increased in the last decade, alongside memory services
investment driven by the Dementia strategies [6] and inclu-
sion of Dementia in the UK Quality and Outcomes
Framework (QOF) pay-for-performance system; the propor-
tion of dementia undiagnosed, while still substantial, has
decreased in recent years [7].
Inequalities in healthcare access reduce the effectiveness
of health policies. People from minority ethnic groups are
diagnosed with dementia later in the illness, and those from
Black ethnic groups are 30% less likely to receiving cholin-
esterase inhibitors [8]. Socioeconomic inequalities are less
well studied. In Australia (2003–10), cholinesterase inhibitors
were prescribed more to less deprived people [9]. In small,
probably unrepresentative UK studies, people with dementia
who were younger, more deprived [10], from a lower social
class or less educated were least likely to receive anti-
dementia drugs [11].
In the current study, we investigated for the ﬁrst time in-
equalities in NHS national dementia prescribing and how
they have varied over the past decade, which has seen an
abundance of dementia policymaking. Our objectives were
to test our hypothesis that people in the most deprived
quintile were less likely than the least deprived to be pre-
scribed anti-dementia drugs between 2002 and 2013. We
also hypothesised a priori that: (i) National Dementia
Strategies and reversal of previous restrictions in prescrib-
ing for mild dementia reduced deprivation inequalities in
initiation of prescribing after 2010, by reducing a tendency
towards less prescribing in more deprived areas, where
primary care is relatively under-resourced [12] and patients
may be less knowledgeable and assertive in seeking out
treatment [13]; (ii) less restrictive recommendations in
Scotland compared with other UK countries between 2006
and 2009 resulted in less inequality by deprivation in
Scotland.
Methods
Data source
Approximately 98% of the UK population are registered
with a GP [14] and over 90% of NHS contacts are in general
practice [15]. The Health Improvement Network (THIN) is
a primary care database of 12 million patients (http://www.
csdmruk.imshealth.com). Anonymised patients’ data are col-
lected from over 500 participating practices that are broadly
representative of UK practices in terms of patients’ age and
sex, practice size and geographical distribution [16]. Broadly
reﬂecting the distribution of UK practices [13], most THIN
practices are in England (73%), with 15% in Scotland, 8%
in Wales and 4% in Northern Ireland. GPs record medical
diagnoses and symptoms using the Read classiﬁcation
system [17]. Prescription information is entered automatical-
ly. Information recorded for each registered person includes
year of birth, sex, diagnoses and symptom records, prescrip-
tions and quintiles of deprivation score.
Study population
We included patients aged 50 or over with a dementia Read
code or at least one anti-dementia drug prescription. We
included patients with an anti-dementia drug prescription
even if no dementia diagnosis was recorded, as they are only
prescribed for dementia. for each practice, we only used data
from the date when death recording was considered com-
plete, and computer usage levels acceptable [18, 19]. The
cohort was restricted to patients for whom deprivation score
quintile was available (98%). This was a dynamic cohort,
with patients entering and leaving at difference times.
Patients were included from the latest of registration date, age
50 years, or 1st January 2002. Patients were followed from
their earliest record of dementia or anti-dementia drug pre-
scription, and follow-up was censored at the earliest date of
death, leaving the practice, or 31st December 2013.
Measurements
We included people with Read codes for non-speciﬁc demen-
tia, Alzheimer’s disease, vascular dementia and all other
dementias. The GPs do not always record the subtype diag-
nosed by a specialist. We examined deprivation by using quin-
tiles of the Townsend score [20], which is linked to a patient’s
UK postcode and is based on levels of unemployment, car
ownership, home ownership and household overcrowding
recorded in the 2001 census. In a sensitivity analysis, we used
an alternative measure of deprivation: quintiles of the 2007
Index of Multiple Deprivation (IMD) [21] for England. The
IMD is based on levels of income, employment, health, educa-
tion, crime, access to services and living environment. It is
only internally valid within countries, and so this sensitivity
analysis was restricted to English practices. We deﬁned initi-
ation of anti-dementia therapy as receiving at least one pre-
scription and continuation as receiving 60 consecutive days of
doses [22].
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Analysis
Using Stata version 13.1, we calculated incidence rate ratios of
anti-dementia drug initiation in a univariable analysis stratiﬁed
by age, gender, country, deprivation score and time period. We
used a Poisson multivariable regression to measure associations
between deprivation and anti-dementia drug prescribing after
accounting for covariates. Analyses used random-effects
regression to account for practice clustering effects. As we
found a signiﬁcant interaction between deprivation quintile and
country, we ﬁtted separate models to data from each country
to investigate the effect of deprivation on anti-dementia drug
prescribing. We repeated analyses to investigate drug continu-
ation. We conducted a sensitivity analysis including only those
with a known subtype diagnosis for which medication is
recommended (Alzheimer’s disease, mixed Alzheimer’s and
vascular and Lewy Body and Parkinson’s disease dementias).
We repeated our main analysis in English practices using the
2007 IMD for England instead of Townsend score to measure
deprivation. This work was supported by The Dunhill Medical
trust (R296/0513).
Results
We included 77,045 patients with a record of dementia or an
anti-dementia drug prescription, with a median (inter-quartile
range [IQR]) follow-up of 1.8 (0.8–3.3) years. Table 1 shows
study cohort characteristics. Dementia diagnosis subtype was
unspeciﬁed for 36,108 (47%) patients; 23,351 (30%) patients
had an Alzheimer’s or mixed dementia diagnosis; and 15,346
(20%) patients had a vascular dementia diagnosis.
Drug initiation
A total of 28,337 (37%) patients received at least one anti-
dementia drug prescription, with an overall drug initiation
rate of 23 per 100 person-years. In total, 17,704 (62%) of
prescriptions were for donepezil, 3,541 (12%) rivastigmine,
4,232 (15%) galantamine and 2,860 (10%) memantine. The
crude drug initiation rate in the most deprived dementia
patients was 21.7 per 100 person-years, but 26.1 per 100
person-years in the least deprived (Table 2). Least deprived
patients were 25% more likely to be initiated on an anti-
dementia drug than the most deprived patients (adjusted in-
cidence rate ratio [IRR] 1.25, 95% conﬁdence interval [CI]
1.19–1.31). Drug initiation rates were higher in younger
people and men. Initiation rates were lowest in Wales (IRR
0.68, 95% CI 0.55–0.82) and highest in Northern Ireland
(1.81, 1.41–2.34) and Scotland (1.14, 0.98–1.32) (Table 2).
Drug initiation rates appeared to be slightly lower during
2006–09 compared with 2002–05 and 2010–13 in all coun-
tries (Figure 1). In English practices, a similar relationship
was observed to that seen in the whole UK, with rates of
prescribing increasing with decreasing deprivation (least
deprived compared with the most deprived group: IRR 1.27,
95% CI 1.20–1.34). In the other UK countries, there was no
such relationship between deprivation quintile and
prescribing (Table 3). Figure 1 indicates that in Wales, greater
deprivation may have been associated with less prescribing
before 2010, although from 2010–13, this relationship is no
longer evident.
Drug continuation
There was no signiﬁcant difference in the likelihood of
people from different deprivation quintiles receiving anti-
dementia drugs for at least 60 days. Continuation rates were
similar between countries.
Sensitivity analyses
When we restricted the analysis to people with a known diag-
nosis for which anti-dementia drugs are indicated (primarily
Alzheimer’s and mixed dementias): the least deprived had a
7% higher rate of drug initiation than the most deprived
group (IRR 1.07, 95% CI 1.01–1.15). Using IMD instead of
Townsend score to measure deprivation in England, we
observed a similar relationship between deprivation and anti-
dementia drug prescribing; the least deprived had a 33%
higher rate of drug initiation than the most deprived group
(IRR 1.33, 95% CI 1.24–1.41).
Discussion
People with dementia who were least deprived were 25%
more likely than the most deprived to be prescribed anti-
dementia medication; this was driven by data from English
practices, where the least deprived were 27% more likely to
be prescribed these drugs. Dementia drug treatments have
probably been more available to people who are less
deprived, because they better negotiate healthcare systems,
and more frequently ask for them [13]; and less available to
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1. Cohort characteristics at baseline
Characteristics n (%)
Sex
Male 27,773 (36)
Female 49,272 (64)
Age at baseline
Median (IQR) 82 (77–87)
Country
England 59,498 (77)
Scotland 10,231 (13)
Wales 4,712 (6)
Northern Ireland 2,604 (3)
Year of first dementia record
2002–05 19,074 (25)
2006–09 26,461 (34)
2010–13 31,510 (41)
Townsend quintile
1 (least deprivation) 18,547 (24)
2 18,114 (24)
3 16,846 (22)
4 14,570 (19)
5 (greatest deprivation) 8,968 (12)
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. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2. Rates and predictors of anti-dementia drug initiation
Characteristics Rate of drug initiation
per 100 person-years
IRRa (95% CI)
Unadjusted Adjusted
Sex
Male 25.0 1 1
Female 22.1 0.87 (0.85–0.89) 0.96 (0.94–0.98)
Age
per 10 year increase 0.77 (0.76–0.78) 0.76 (0.75–0.77)
Country
England 22.5 1 1
Scotland 25.8 1.17 (1.02–1.36) 1.14 (0.98–1.32)
Wales 14.2 0.72 (0.59–0.87) 0.68 (0.55–0.82)
Northern Ireland 44.7 1.90 (1.48–2.44) 1.81 (1.41–2.34)
Year
2002–05 22.5 0.74 (0.72–0.77) 0.72 (0.69–0.74)
2006–09 19.5 0.68 (0.66–0.69) 0.67 (0.65–0.68)
2010–13 25.9 1 1
Townsend quintile
1 (least deprivation) 26.1 1.24 (1.18–1.30) 1.25 (1.19–1.31)
2 22.9 1.11 (1.06–1.17) 1.14 (1.09–1.20)
3 22.6 1.12 (1.07–1.18) 1.13 (1.08–1.19)
4 20.9 1.06 (1.01–1.12) 1.07 (1.02–1.12)
5 (greatest deprivation) 21.7 1 1
aResults from multivariable Poisson regression models, including practice as a random effect. Adjusted IRRs are adjusted for the other covariates shown.
IRR, incidence rate ratio.
Figure 1. Plots of initiation rates over time by Townsend score and country.
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those from more deprived areas, who have on average more
morbidity, attend relatively under-resourced practices and are
less able to attend appointments, especially in rural areas [12,
23]. These differences are signiﬁcant, although of a lesser
magnitude to those reported in other Western countries [6].
In England, signiﬁcant inequality remained throughout the
decade studied despite the 2010 National Dementia strategy
and more inclusive 2009 NICE guidelines [24]. Guidelines
can take years to be fully implemented [25], so these policies
could be driving inequality reductions not fully realised,
although our study extended 4 years after guideline publica-
tion. In Wales, there appeared to be less inequality after 2010;
this could be a chance ﬁnding or indicate that these policies
have more effectively reduced inequality in Wales.
People in Northern Ireland with dementia are more likely
than those in England to be prescribed anti-dementia drugs,
and there was a trend towards more prescribing in Scotland.
We hypothesised that the less restrictive Scottish recommen-
dations between 2006 and 2009 might have decreased dispar-
ity in their use compared with England, because people
with fewer resources are less able to circumvent restrictions
[13]. The disparities in treatment availability that we found in
English practices were not demonstrated in Scottish or
Northern Irish practices. Perhaps the higher overall prescrib-
ing rates in Scotland and Northern Ireland helped prevent
prescribing inequalities. In Scotland and Northern Ireland, a
greater proportion of patients with dementia have a recorded
diagnosis, compared with English and Welsh practices, so
people with dementia could also be more likely to receive a
timely diagnosis in these countries [26].
The proportion of prescribing taking place in primary
versus secondary care might be greater in Scotland where, in
contrast to England, primary and secondary health care are
more integrated, and GPs with experience in dementia may
diagnose and initiate treatment [27]. In England and Wales,
NICE guidelines recommend specialist initiation [28], so it
might be harder for people with dementia, and those with
fewer economic resources especially, to access prescribing.
The Northern Irish health system is relatively less integrated,
however, so integration does not explain our ﬁndings from
this region.
Levels of investment in health, including memory services,
vary between UK countries since devolution. Government
health spending is lowest in England and highest in Scotland
and Northern Ireland, although these variations have declined
over the past decade [29]. We found the lowest overall pre-
scribing rates in Wales, where memory clinic funding per new
patient is half that of English memory clinics [30] and fewer
dementia cases are diagnosed compared with the other UK
countries [7].
Limitations
Having a dementia diagnosis depends on patients presenting
and doctors (usually in secondary care) recording a diagnosis.
Dementia is under-recorded in GP records [31]. In a UK
study higher diagnosis rates were associated with greater
practice deprivation, perhaps because deprived groups have
more chronic illnesses that are associated with dementia and
more frequent GP contact [32]. Multiple morbidity is more
common in deprived areas, so perhaps some of the
decreased prescribing in these areas might relate to concerns
about side effects in those who are more physically frail [12].
We do not know whether the large group of people with
subtype dementia unspeciﬁed had potentially treatable condi-
tions. Vascular dementia is the most common dementia for
which anti-dementia drugs are not indicated, and its prevalence
would be expected to be greater in more deprived groups who
have higher cardiovascular morbidity [33]. This could explain
the lower treatment rates with deprivation; in our sensitivity
analyses restricted to those with treatable subtypes, results were
in the same direction but of lower magnitude. This is probably
because subtype diagnoses are often entered into records when
medication is started; in a previous study, people from more
deprived groups were more likely to have a diagnosis of demen-
tia subtype unknown [10]. Treatments exclusively in secondary
care would have not been detected and this may have happened
more to those less deprived, as access to secondary care is
probably reduced by deprivation [23], thus excluding this group
could underestimate the extent of inequalities. Dementia is the
only UK licensed indication for cholinesterase inhibitors, and
prescribing for another disorder is unlikely. Some recorded
cases of dementia may be misdiagnosed.
The Townsend score characterises deprivation in a par-
ticular form: for example it does not measure wealth, social
mobility and educational attainment directly. Car ownership
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3. Association between Townsend quintile and anti-dementia drug initiation in the four constituent countries of the UK
Characteristics England Scotland Wales Northern Ireland
IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI)
Townsend quintile
1 (least deprivation) 1.27 (1.20–1.34) 1.15 (1.01–1.30) 1.09 (0.86–1.38) 1.00 (0.84–1.18)
2 1.11 (1.05–1.17) 1.34 (1.21–1.49) 0.94 (0.74–1.19) 1.07 (0.90–1.28)
3 1.09 (1.03–1.16) 1.32 (1.19–1.47) 0.95 (0.76–1.19) 1.16 (0.98–1.37)
4 1.02 (0.96–1.08) 1.30 (1.17–1.44) 0.91 (0.72–1.16) 1.08 (0.89–1.30)
5 (greatest deprivation) 1 1 1 1
Results from multivariable Poisson regression models, including practice as a random effect. IRRs adjusted for sex, age and calendar time.
IRR, incidence rate ratio.
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is included in the score but this may be a less useful depriv-
ation index in urban compared with rural areas, illustrating
the importance of a composite measure. Some people will be
assigned the wrong deprivation level, because they live in a
neighbourhood that is more or less deprived than their per-
sonal circumstances, and this is most likely in dense, inner
city areas. Care home locations may not reﬂect the depriv-
ation level of residents, so for the minority of people with
dementia who live in care homes, scores may not have been
accurate. Townsend scores calculated at the enumeration
district level are however strongly correlated with individual
deprivation and are similarly predictive of health [34]. The
IMD is now most frequently used, but as it cannot be used
to directly compare the different UK countries [35], it was
not our primary outcome. In our sensitivity analysis, ﬁndings
using the Townsend and IMD indices were very similar.
Conclusions
People with dementia who were least deprived were 25%
more likely than the most deprived to be prescribed anti-
dementia medication. This ﬁnding appeared to be driven by
English practice data, while in Scottish and Northern Irish
practices there was no such evidence of inequity. These
differences could relate to health policies of the countries,
which have diverged since devolution. Higher overall anti-
dementia drug prescribing in Scottish and Northern Irish
practices and differing clinical guidelines in Scotland from
other UK countries might explain apparently greater equality
in prescribing in these countries. Strategies to offer treatment
to more deprived people with dementia in England are ur-
gently needed. These should focus on increasing the propor-
tion of people with dementia of all severities offered drug
treatments, and seeking to ensure that future prescribing pol-
icies do not introduce barriers to care that are less penetrable
to people from the most deprived areas.
Key points
• Least deprived patients were 25% more likely to be initiated
on anti-dementia drugs than the most deprived in the UK.
• We found that there were inequalities by deprivation in anti-
dementia drug prescribing in England but not the other
UK countries.
• Strategies to offer treatment to more deprived people with
dementia in England are needed.
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